Edward J. Primka III, M.D.

Biographic:

Born: August 16, 1965

Address: Dermatology Associates of Knoxville, P.C.
939 Emerald Ave., Suite 705
Knoxville, Tennessee 37917
August, 2001-Present

11416 Grigsby Chapel Road, Suite 100
Knoxville, Tennessee 37934

7557 Dannaher Way, Suite G20
Powell, TN 37849

Positions:

Section Head of Regional Dermatology
Cleveland Clinic Foundation
Cleveland, Ohio
1999-2001

Staff, Cleveland Clinic Foundation, Department
of Dermatology, Cleveland, Ohio
February 1999-2001

Associate Staff, Cleveland Clinic Foundation
Department of Dermatology, Cleveland, Ohio
January 1998-February 1999

Clinical Associate, Cleveland Clinic Foundation
Department of Dermatology, Cleveland Ohio
January 1997-January 1998

Medical: Cleveland Clinic Foundation, Department of Dermatology and
Biomedical Engineering, Research Fellow, Cleveland, OH
July 1996-December 1996

Cleveland Clinic Foundation, Department of Dermatology

Residency Program, Cleveland, OH
July 1992-June1996

University of North Carolina School of Medicine, Chapel
Hill, N.C. M.D. with Honors and Distinction
May 1992

College: Wake Forest University, Winston-Salem, N.C.
B.S. Biology, Cum Laude
1988

Post-Graduate:

Residency: Cleveland Clinic Foundation Department of Dermatology
Residency Program, Cleveland, OH
July 1992-June1996

Board:

Board Certified
American Board of Dermatology
October 14, 1996

Diplomate
National Board of Medical Examiners

July 1993

Publications:

Psoriasis and bullous pemphigoid treated with azathioprine.
J am Acad Dermatology 39:121-3, 1998

Three cases of contact allergy following chemical burns from
Methylchloroisothiazolinone/Methlisothiazolinone-one with
Concomitant allergy to Methyldibromogiutaronitrille/Pheno-
xyethanol. Am J Cont Dermatitis, 8: 43-46m 1997

Methotrexate induced epidermal nerolysis in a patient with
Psoriasis. JAAD 36:815-8, 1997

Cellular Dermatofibroma, Dermatologic Surgery 23: 711-713,
1997

Bullous Amyloidosis, JAAD 32: 539-44, 1995

Amiodarone induced linear IgA disease, JAAD 31: 809-11, 1994

Malignant melanoma of unknown origin presenting a systemic
vasculitis. Arch Dermatology 129: 1205-07, 1993

Pigmented purpuric dermatosis in a young male. Cutis 63:112-113
1999
Abstracts:

Primka EJ, Tammi R, Hascall V, Bergfeld W. Decreased expression of Hyaluronan and CD 44 in alopecia areata. J Invest Dermatol, April, 1996

Primka EJ, Tammi R, Bergfeld W., Hascall V. Metastatic
Basal cell carcinomas fail to express CD 44. J Cut Path, Feb 97

Primka EJ, Gay D., Bergfeld WF. Drug induced linear IgA disease
Histologic features of three cases. J Cut Path 23:58, 1999

Taylor JS, Primka EJ., Hamaty F. Latex allergy: review of thirty
Eight cases of hand eczema and outcome. European Society of Contact Dermatitis, Oct. 94.

Liranzo MO, Bergfeld WF, Primka EJ, Hengel RL, Tomford
JW. Detection of cytomegalovirus antigen in a patient with
leukocyoclastic vasculitis. J. Cutaneous Pathology 20:553, 1993.

Primka EJ, Liranzo MO, Bergfeld WF. An unusual blistering
Dermatosis: a case presentation of bullous amyloid. J Cutaneous
Pathology 20:563, 1993.

Posters:

Primka EJ, Tammi R, Bergfeld W, Hascall V. Metastatic basal
Cell carcinomas fail to express CD 44, American Society of
Dermatopathology, San Francisco, March 1997.

Liranzo MO, Bergeld WF, Primka EJ, Hengel RI, Tomford JW.
Detection of cytomegalovirus antigen in a patient with leuko-
Cytoclastic vasculitis. American Society of Dermatopathology,
Baltimore, December 1993.
CURRICULUM VITAE PAGE 4 EDWARD J. PRIMKA, MD.

Primka EJ, Liranzo MO, Bergfeld WF. An unusual blistering
Dermatosis: a case presentation of bullous amyloid. American
Society of Dermatopathology, Baltimore, December 1993.

Medical Honors:

Alpha Omega Alpha Medical Honor Society, elected junior year,
UNC School of Medicine, 1991.

Alumni Loyalty Award 1991 (Recognizes students with the highest
academic achievement during an academic year).

Loyalty Fund J.S. Gaul Merit Award 1991 (Recognizes students
whose academic performance in surgery was distinguished).
Merit Award Honors Scholarship, UNC School of Medicine, 1989-
1991. (1989 and 1990 given to students in the top 15% of the class.
1991 given to students in the top 25%).

Fourth Year Merit Award (Recognizes students who received
Honors for their first, second, and third year academic perform-
ance).

Professional Society Memberships:

• American Medical Association, 1989-Present
• Alpha Omega Alpha, 1991-Present
• American Academy of Dermatology, 1993-Present
• Society of Investigative Dermatology, 1996-Present
• Cleveland Dermatologic Society, 1997-Present
• Ohio Dermatologic Association, 1997-Present
• Ohio Society of Dermatologic Surgeons, 1997-Present
• American Society of Contact Dermatitis, 1999-Present

Research:

Skin Cancer Database, Visualization and Analysis System
#34-1865201

Decreased expression of hyaluronan and CD44 in Alopecia
Areata. Cleveland Clinic Research Institution, Vincent Hascall,
PhD. 1995

A double-blind, placebo-controlled study of a medication in the
Treatment of distal subungual onychomycosis of the toenail, 1994-
1995

Expression and purification of 37-KD adherens junction protein
from glutathione-S-transferase fusion protein. Department of
Dermatology, UNC School of Medicine, 1992
The expression of c-fos-like protein as an anatomical marker for
noxious stimulation in the rat. Department of Physiology, UNC
School of Medicine, 1992

A Phase II Randomized, Double-Blind, Placebo-Controlled,
Multiple –Dose, Dose-Finding, Safety, and Efficacy Study
Of a Monoclonal Antibody in Patients with Moderate to Severe
Psoriasis.

A Phase III, Vehicle Controlled Study of a Topical Gel for Each
Recurrence of Herpes Genitalis over a 12 Month Period.

A Multi-Center, Randomized, Placebo-Controlled Phase 2 Study
Evaluating the Effect of a Intradermal Injection as Compared to
Placebo in Patients with Psoriasis.

A Randomized, Third Party Blind, Multi-Center Trial Comparing
The Efficacy and Safety of an Oral Med for 3 Weeks Versus a
Second Oral Med for 6 Weeks Versus a Third Oral Medication
For 6 Weeks Given Once Daily to Pediatric Patients with Tinea
Capitis.

A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Safety of a Subcutaneously Administered Medication in Adults with Moderate
to Severe Plaque Psoriasis who are Candidates for Systemic
Therapies.

A Randomized, Double Blind, Placebo Controlled, Parallel Group
Study to Assess the Safety and Efficacy of Three Dose Levels of
a Tablet in the Treatment of Chronic Plaque Psoriasis.

A Multi-Center, Randomized, Double-blind, Vehicle-controlled,
Dose-finding, Bilateral Plaque Comparison Study of the Safety
And Efficacy of Three Concentrations of an Ointment in the
Treatment of Mild to Moderate Plaque Psoriasis.

A Double-blind, Randomized, Vehicle-controlled Trial Comparing the Efficacy and Safety of a Lotion versus Vehicle in the
Treatment of Atopic Dermatitis or Eczema in Adult Subjects.

A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter, Efficacy and Safety Study of a Nail Lacquer
Versus Vehicle for the Treatment of Onychomycosis.

Efficacy and Safety of a Shampoo in the Prevention of Relapse of
Seborrheic Dermatitis of the Scalp.

An Open-Label, 18-Month Safety study of a Cream for the Treatment of Actinic Keratosis.

A Multicenter, Open Label Study to Observe the Effect of a Subcutaneous Injection on Joint and Skin Disease in Subjects with Psoriatic Arthritis.

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group
Multi-Center Study to Demonstrate the Safety and Clinical Equivalence of a Generic Lotion in the Treatment of Inflammatory Papules and Pustules of Rosacea.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Administration of an IM medication to subjects with Moderate to Severe Plaque Psoriasis.

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multi-Site Study to Evaluate the Bioequivalence of a Topical Gel Formulation in Patients with Moderate to Severe Rosacea.

An Open-Label Community-Based Study to Determine the Safety and Efficacy of an Extended Course of an injection which follows a Standard 12-Week course for the Treatment of Psoriasis.

A Multicenter, Randomised, Double-blind, Placebo controlled, Phase III study of a Subcutaneously Administered Study Drug in the Treatment and Re-treatment of Subjects with Moderate to Severe Plaque Psoriasis.

A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of a Study Foam versus an FDA approved Cream in the treatment of Seborrheic Dermatitis.

A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects with Acne Vulgaris treated with a Gel.

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Shampoos in Patients with Tinea (Pityriasis) Versicolor.

A Phase III, Randomized, Evaluator-Blind, Parallel Group Study of the Efficiacy and Safety of Tablets, Capsules, and Placebo in the Treatment of Onychomycosis of the Toenail.

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Creams in Patients with Interdigital Tinea Pedis.

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multi-Site Study to Evaluate the Bioequivalence of Two Ointments and Placebo in Patients with Moderate to Severe Psoriasis.